Abstract:The peptidoglycan-polysaccharide (PGPS) model shares many etiologic and pathologic features with Crohn's disease (CD).Anti-TNFα therapy reduces both inflammation and fibrosis in the PGPS model if begun early but, as in CD, has diminished efficacy when instituted late in the course of the model.To begin to tease out the mechanism of diminished anti-TNFα efficacy in advanced disease, we examined changes in mRNA levels of a broad panel of proinflammatory and profibrotic factors over time in the PGPS model.Methods: PGPS or human serum albumin (HSA, control) was injected into the bowel wall of Lewis rats at laparotomy.Rats (1 HSA, 3 PGPS) were euthanized at each time point (1, 4, 7, 11, 14, 21, and 28 d post injection).Non-operated rats (3) served as d0 controls.In separate experiments, rats received Ab501 (CA156_00501 Fab'-PEG; a pegylated murinized rabbit anti-mouse TNF) beginning on d1 or d13.Rats receiving anti-TNF were studied on d12 or d28.Gross abdominal score (sum of adhesions, mesenteric thickening, cecal wall thickening, cecal nodules, and liver nodules on 0-4 scales) was determined.A pathologist scored cecal sections.Quantitative real-time PCR was performed on cecal tissue.Results: IL1 β, IL6, TNFα, and TGFβ1 mRNAs showed a biphasic response, peaking at d1 and again at d11 post PGPS injection (previously shown).The second peak at d11 was accompanied by maximal mRNA levels of Th1 (IFNγ, IL2) and Th17 (IL17A) cytokines, IL23, granulocyte-macrophage colony stimulating factor (GM-CSF), monocyte chemotactic protein-1, arginase-1, tissue transglutaminase 2, and tissue inhibitor of metalloproteinase 1. Osteopontin mRNA was maximally elevated at d1 (.500-fold), then progressively declined to ~40-fold control at d21-28.IL13 mRNA was not elevated.Anti-TNF begun on d1 decreased expression of IL1 β (5.5±1.8 v 12.8±1.2,p=0.014) and IL6 (11.2±6.6 v 51.5±7.6,p=0.008) when assessed on day 12. Anti-TNF begun on d13 did not change expression of TNF α, IL1β, IL6 mRNAs; procollagens I and III trended higher on d21 (col I: 23.1±6.2v 11.6±1.9,p=0.07; col III: 14.7±2.1 v 9.14±1.7,p=0.06).Conclusions: The robust Th17 response and increased GM-CSF near the midpoint of the PGPS model time course may render the ongoing immune response no longer controllable by targeting TNF α alone.Blockade of TNF α activity initiated at times in the course of disease when TGF β1 mRNA expression is maximal could exaggerate the results of loss of TNF α inhibitory effects on TGF β profibrotic activity.This could explain why anti-TNFα begun on d13 results in increased collagen mRNA at d21.Decreased tissue compliance, suggested by increased collagen deposition at d7, may play a role in triggering the d7-11 wave of increased profibrotic and proinflammatory factors.Cytokine milleu and tissue factors likely determine the effect of anti-TNF on tissue inflammation and fibrosis.

Macrophage Deficiency Makes Intestinal Epithelial Cells Susceptible to NSAID-Induced Damage.

Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD

Sa1797 Cell Cycle Arrest, DNA Damage and Remodeling of the Colonic Epithelial Barrier Composition and Function Underlies DSS-Induced Colitis

CD1d1 Intrinsic Signaling in Macrophages Controls NLRP3 Inflammasome Expression During Inflammation.

Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease

The absence of interleukin 10 affects the morphology, differentiation, granule content and the production of cryptidin-4 in Paneth cells in mice

Dynamic role of macrophage CX3CR1 expression in inflammatory bowel disease

Decreased TMIGD1 aggravates colitis and intestinal barrier dysfunction via the BANF1-NF-κB pathway in Crohn's disease

Intestinal CD14+ Macrophages Protect CD4+ T Cells from Activation-induced Cell Death Via Exosomal Membrane TNF in Crohn's Disease.

Irgm1-deficient mice exhibit Paneth cell abnormalities and increased susceptibility to acute intestinal inflammation

Mincle/Syk Signalling Promotes Intestinal Mucosal Inflammation Through Induction of Macrophage Pyroptosis in Crohn’s Disease

Deficiency in Intestinal Epithelial O‐GlcNAcylation Predisposes to Gut Inflammation

The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease

NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis

Synergistic Action of Diclofenac with Endotoxin-Mediated Inflammation Exacerbates Intestinal Injury in Vitro

Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease

CD169 Expressing Macrophage, a Key Subset in Mesenteric Lymph Nodes Promotes Mucosal Inflammation in Dextran Sulfate Sodium-Induced Colitis

Eating the enemy in Crohn's disease: an old theory revisited

ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation

Mdscs Are Involved in the Protumorigenic Potentials of Gm-Csf in Colitis-Associated Cancer

Defective macrophage handling of Escherichia coli in Crohn's disease